LifeSci Capital analyst Adam Evertts PhD reiterated a Buy rating on Odonate Therapeutics (ODT – Research Report) today and set a price target of $50.00. The company’s shares closed last Wednesday at $15.14, close to its 52-week low of $12.56.
According to TipRanks.com, PhD is ranked #4486 out of 7016 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Odonate Therapeutics with a $50.00 average price target.
The company has a one-year high of $46.50 and a one-year low of $12.56. Currently, Odonate Therapeutics has an average volume of 451.1K.
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ODT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.